insulin aspart
NovoLog (insulin aspart) is a rapid-acting insulin from Novo Nordisk. A single amino acid change makes it absorb quickly after injection, so it covers the rise in blood sugar that follows a meal, and it is used in type 1 and type 2 diabetes.
This page is based on FDA prescribing information and the EMA medicine record for insulin aspart; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
Think of insulin as the building manager who unlocks cells so glucose can come in. After a meal, blood sugar rises fast and the body needs many managers right away. Insulin aspart is a fast-acting stand-in: injected just before eating, it dissolves into active molecules within minutes, opening the doors quickly so glucose from the meal can move into cells.
In simple terms
Insulin is the hormone that lets cells absorb glucose from the blood. After a meal, blood sugar rises quickly, and the body needs a fast burst of insulin. Insulin aspart is a modified human insulin designed to act rapidly. Injected under the skin just before a meal, it is absorbed quickly and starts working within minutes, covering the rise in blood sugar that follows eating. Its effects peak in about one to three hours and fade over three to five hours.
In depth
Insulin aspart differs from human insulin by a single substitution of aspartic acid for proline at position B28, which reduces self-association of hexamers and accelerates absorption from the subcutaneous depot. The resulting rapid rise in insulin levels mirrors the prandial insulin response of a person without diabetes. It is equipotent with human insulin on a molar basis but has a faster onset and shorter duration. It is used as mealtime insulin and may be formulated as a mixture with protamine-retarded insulin aspart for combined prandial and basal coverage.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How the B28 aspartic-acid swap makes insulin aspart act fast
- Insulin aspart differs from human insulin by a single substitution of aspartic acid for proline at position B28, which reduces self-association of hexamers and accelerates absorption from the subcutaneous depot.
- Its effects peak in about one to three hours and fade over three to five hours.
- It is equipotent with human insulin on a molar basis but has a faster onset and shorter duration.
- It is used as mealtime insulin and may be formulated as a mixture with protamine-retarded insulin aspart for combined prandial and basal coverage.
Target: Insulin receptor
The receptor through which insulin tells muscle, fat, and liver cells to take up glucose; a rapid-acting insulin covers the spike in blood sugar that follows meals.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- To improve glycemic control in adult patients with diabetes mellitus
Approved uses in European Union
EMA- Treatment of diabetes mellitus in adults, adolescents, and children aged 1 year and above
Official sources
The statements on this page trace back to these records.
- U.S. Food and Drug Administration: NovoLog Mix 70/30 (insulin aspart) prescribing information
U.S. Food and Drug Administration
- NovoRapid (insulin aspart) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- Emc SmPC: Insulin Aspart (UK licensed product)
Medicines and Healthcare products Regulatory Agency (EMC)
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.